Structure and Function of N-Terminal Zinc Finger Domain of SARS-CoV-2 NSP2

Virologica Sinica - SARS-CoV-2 has become a global pandemic threatening human health and safety. It is urgent to find effective therapeutic agents and targets with the continuous emergence of novel...     

PML Suppresses Influenza Virus Replication by Promoting FBXW7 Expression

Virologica Sinica - Influenza A viruses (IAV) are responsible for seasonal flu epidemics, which can lead to high morbidity and mortality each year. Like other viruses, influenza virus can hijack...     

A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice

Virologica Sinica - SARS-CoV-2 has caused more than 3.8 million deaths worldwide, and several types of COVID-19 vaccines are urgently approved for use, including adenovirus vectored vaccines....     

高通量转录组RNA-seq研究成年牛下丘脑-垂体-卵巢

肉牛的性成熟受下丘脑-垂体-卵巢(HPO)轴的调节,但其具体作用机制尚不清楚.为了探讨HPO轴繁殖相关基因和调控机制,采用高通量转录组RNA-seq技术,研究了成年安格斯牛(30个月大)的下丘脑、垂体和卵巢.结果表明,HPO共有18 179个基因在GO(基因本体论)中注释,37 158个基因在KEGG(京都基因百科全书和基因组)中注释,36 645个基因在KOG(KEGG同源数据库)中注释.GO分析表明,HPO富集了8种生殖相关功能,主要是受精、单个组织生殖过程、子宫胚胎发育和雌激素反应.KEGG分析发现,HPO富集300条信号通路(SP),主要是癌症SP和磷脂酰肌醇3激酶蛋白激酶(PI3K-Akt)SP.与生殖有关的SPs共有16条,主要是Notch SP、神经营养素SP、哺乳动物雷帕霉素(mTOR)SP和血管内皮生长因子(VEG F)SP.为今后肉牛繁殖性能的提高、分子育种和同行参考提供了科学依据.     

植物CBL-CIPK信号系统响应非生物胁迫的调控机制

钙调磷酸酶B蛋白(CBLs)及其互作蛋白激酶(CIPKs)组成的信号系统是非生物逆境响应的重要调控网络。CBL-CIPK系统通过磷酸化感应并解码Ca²⁺信号, 参与植物对非生物胁迫的应答调控。该文综述了CBLs和CIPKs结构、CBLs-CIPKs对不同底物磷酸化及其响应非生物胁迫调控机制的研究进展, 并展望了未来的研究方向, 以期为作物抗逆性遗传改良提供思路。     

Thermococcus sp.B1001环糊精酶的重组表达及在麦芽七糖制备中的应用

成功构建pET-24a-tscd质粒,实现Thermococcus sp.Strain B1001来源的环糊精酶(TsCDase)在Es-cherichia coli BL21(DE3)中表达.通过热处理和镍柱分离对重组TsCDase进行纯化.酶学性质研究表明,重组TsCDase的比活为1 208.04 U/mg,最适温度为90℃、最适pH值为5.5.重组酶TsCDase在85℃、90℃、95℃条件下的半衰期分别为180、120、30min.酶转化研究表明,以80 g/L β-环糊精为底物,当酶转化温度为90℃、反应pH值为5.5～6.0,加酶量为25 U/g,反应时间为4 h时,麦芽七糖产率为81.19％和85.95％,七糖占产物麦芽寡糖的比例为95.24％和92.92％.本研究结果为工业化制备麦芽七糖奠定良好基础.     

Application of germ-free NOD-scid IL2rgnull mice as a humanized model for tumor microbiome precision medicine

正In 2013, tumor immunotherapy topped the list of the top ten scientific breakthroughs(Couzin-Frankel, 2013), and it was widely used in the treatment of lung cancer, kidney cancer,and melanoma(Routy et al., 2018). However, the response rate of patients to tumor immunotherapy varies, and usually,only a small percentage of patients respond well to treatment(Sambi et al., 2019).